Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- AbbVie Seeks Japan Approval for Psoriasis Drug Risankizumab
May 28, 2018
- Opdivo/Yervoy Combo Gains Japan Nod for Melanoma
May 28, 2018
- 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
- Otsuka/Lundbeck to Launch Add’l PIII for Brexpiprazole in June
May 25, 2018
- Chugai Seeks Still’s Disease Indication for Actemra
May 25, 2018
- Maviret Top Seller Drug in Japan in January-March: IQVIA
May 23, 2018
- Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
- Astellas to Shed 600 Jobs to Revamp Japan Operations
May 23, 2018
- Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
May 23, 2018
- Top 4 Wholesalers Report Unusually Low Growth in Drug Wholesale Business for 2nd Year after Price Revision
May 23, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment to Enter PII/III in 1st Half of FY2018
May 23, 2018
- Janssen Files Triple-Combo for HIV Treatment in Japan
May 23, 2018
- Takeda Divests China JV Techpool
May 22, 2018
- Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
May 22, 2018
- AZ Files Forxiga for Expanded Use in Type 1 Diabetes in Japan
May 22, 2018
- Ethical Drug Sales Up 0.2% in FY2017: Crecon Report
May 21, 2018
- Dustin Haines Named as President of ViiV Healthcare Japan
May 21, 2018
- Growject to Enter PIII Study for SHOX Deficiency: JCR
May 21, 2018
- Kyowa Kirin’s Burosumab Hits Primary Endpoint in Multinational PIII Study in XLH Children including Japan
May 21, 2018
- Nobelpharma Becomes Medipal’s Equity Method Affiliate
May 21, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…